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people with psoriasis. Methods: We used the Taiwan’s National Health Insurance 
Research Database to conduct a nationwide population-based cohort study to assess 
the risk of incident CKD and ESRD in people with psoriasis and to further evalu-
ate the respective risk estimates in those with mild and severe psoriasis based 
on treatment patterns. Results: A total of 4,633 psoriatic patients and 922,534 
nonpsoriatic controls were included. Severe psoriasis, but not mild psoriasis, was 
an independent risk factor of incident CKD and ESRD (adjusted hazard ratio being 
1.90 (95% confidence interval 1.33-2.70) and 2.97 (95% confidence interval 1.72-
5.11), respectively) after adjustment for potential confounders including age, gender, 
comorbidities, and used of nonsteroidal anti-inflammatory drugs (NSAIDs). Severe 
psoriasis remained an independent risk factor of incident CKD and ESRD after vari-
ous sensitivity analyses after adjusting for the presence of osteoarthritis and/or 
rheumatoid arthritis, use of methotrexate and/or cyclosporine, and chronic use 
of NSAIDs for at least 2 months. Psoriatic arthritis was an effect modifier for CKD 
and ESRD. ConClusions: The associations of severe psoriasis with CKD and ESRD 
should be recognized. Assessment of renal function and avoidance of long-term 
use of nephrotoxic drugs shall be implemented in the integrative care for patients 
with severe psoriasis.
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objeCtives: To assess co-morbidity, quality of life (QOL), work/productivity loss, 
and medical resource utilization (MRU) in patients suffering from glaucoma in 
Brazil. Methods: Patients self-reported data were collected from 2011-2012 
National Health and Wellness Survey (NHWS -Kantar Health global self-reported 
general population survey in healthcare). QOL was measured by the physical com-
ponent score (PCS) and mental component core (MCS)of the Short Form-12 (SF-12) 
(mean score of 50 for general population). Loss of work/productivity was measured 
by the validated Work Productivity and Activity Impairment (WPAI) instrument. 
MRU was measured by healthcare provider, emergency room (ER) visits and hospi-
talization in the past 6 months.Comparisons were made between respondents who 
were diagnosed with glaucoma vs. respondents without glaucoma (non-glaucoma 
group). Since glaucoma typically affects the adult population, respondents with an 
age of 35 and above were included in the analysis. Results: Among 24,000 survey 
respondents, 242 (1.0%)respondents were diagnosed with glaucoma. The average age 
in the glaucoma group was 53.5 years and 48.2% were male compared to the non-
glaucoma group where average age was 51.6 years with 47.8% male. The Glaucoma 
group reported more co-morbidities, lower mean PCS scores (46.3 vs. 49.4) and MCS 
scores (45.6 vs. 49.0), more healthcare providers visits (93.7%vs.77.4%), ER visits 
(29.6%vs19.0%) and hospitalizations (17.5%vs.9.7%) in the past 6 months compared 
to non-glaucoma group. Also, the glaucoma group reported 36.5% work/productiv-
ity loss (absenteeism and presenteeism) and 33.5% impairments in daily activity 
compared to 17.5% and 22.1% in non-glaucoma group. All comparisons in QOL, 
MRU, and work/productivity loss between two groups were statistically significant 
at P< 0.05. ConClusions: From the Brazil NHWS results, glaucoma patients suffer 
from impairments in quality of life, work/productivity loss,more co-morbidities 
and use of medical services. Findings indicate that glaucoma can have a statistical 
significant impact and negative impact on QOL, MRU and work productivity for 
patients suffering from the disease and for the healthcare system.
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objeCtives: Worldwide, glaucoma is the second highest cause of blindness. 
Surgery is the treatment of choice when medications fail to control intraocu-
lar pressure (IOP). This systematic literature review and meta-analysis aimed to 
compare efficacy and safety of the common surgical options available for pri-
mary angle closure glaucoma (PACG). Methods: Studies with PACG patients 
who underwent trabeculectomy, phacotrabeculectomy or phacoemulsification 
were screened and included from electronic databases. The outcomes compared 
were IOP (24 months), postoperative angle opening distance (AOD), postoperative 
trabecular-ciliary process distance, postoperative anterior chamber depth (ACD), 
synechial angle closure all at 1 year, best corrected visual acuity (BCVA) at 1 year 
and 2 years, and intra- and post-operative complications of the surgery like worse 
logarithmic minimal angle resolution BCVA, progression of glaucomatous optic 
neuropathy, progression of glaucomatous visual field at 2 years. Critical appraisal 
of studies was carried out using Cochrane’s Risk of Bias tool. Meta-analysis of 
clinical trials was conducted using RevMan v5.1, through pooling of medically 
controlled and uncontrolled glaucoma patients where available. Results: Of the 
704 studies that were screened, five randomised clinical trials were included. 
Pooled analysis of two studies showed IOP at 24 months was better controlled by 
phacotrabeculectomy (mean difference 1.46 [95%CI 0.24,2.67]). Post-operative AOD 
and ACD results favoured phacoemulsification (mean difference 123.60 [95%CI 
51.46,195.74] and 230.60 [95%CI 106.30,354.90] respectively). The post-operative 
complications showed risk ratio of 0.07 (95%CI 0.01,0.34) showing fewer com-
plications in phacoemulsification patients. The remaining outcomes showed no 
significant results. Phacoemulsification had significantly lesser complications 
than trabeculectomy, with risk ratio of 0.08 (95%CI 0.01,0.60). The analyses of the 
observational and economic studies are being carried out, the results of which will 
be included in the poster. ConClusions: The results show that while phacotrab-
eculectomy has better IOP control than phacoemulsification, the latter has higher 
safety than both phacotrabeculectomy and trabeculectomy.
use of these drugs increases by 18.0%, Fluoxetine is responsible for the growth 
of 88.5 % in this incidence, with a confidence interval of 95 % and standard error 
of 2%. ConClusions: It was identified that the main molecule used for depres-
sion, in the sample analyzed, was fluoxetine and the age with higher incidence of 
purchases of these drugs is between 20 and 50 years. As WHO data (World Health 
Organization), depression will be the most common disease in the world in 2030. 
The relationship between doctor and patient has a fundamental importance in 
successful treatment. Thus, the patient monitoring is extremely important to con-
trol the disease in the country.
Pmh51
inteGrated clinical Pathway in SchizoPhrenia
Colombo GL1, Valentino MC2, Di Matteo S2, Bruno GM2
1University of Pavia, Milan, Italy, 2S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, 
Italy
objeCtives: mental disorders are a significant problem of public health, espe-
cially for disability they generate during adulthood. They strongly influence qual-
ity of life for patients as well as having important impacts on society and mental 
health services, creating a significant economic problem for the health system 
and for patient. Methods: an integrated clinical pathway (PDTA) for patient with 
schizophrenia has been validated by a group of Italian medical experts. This clinical 
governance tool, enables to organize and integrate activities and interventions in 
a context where, several specialties, professions and areas of action (hospital and 
territorial care) are involved. Results: drug acquisition costs are not the highest 
costs in the schizophrenia management. The highest costs are related to: frequent 
hospitalization, residential care costs, loss of individuals productivity, high costs 
for caregiver. The aim of our work is to offer, to the different actors involved in 
the schizophrenia treatment management, a governance tool (PDTA) that allow: to 
manage the treatment variability, to monitor the resource utilization, to monitor the 
adherence and to improve the quality of processes and outcomes. Also the schizo-
phrenia PDTA, promoting the early use of antipsychotics LAI, answer to the main 
unmet needs in the pathology management: the frequent relapses, the functional 
status preservation and the maintenance of good quality of life. An indicators set 
was validated to monitor the correct adoption of PDTA in order to generate savings 
and better manage the cost of disease. ConClusions: thanks to integrated clinical 
pathway all the actors involved in treating mental disorders are able to outline, the 
best clinical pathway practicable, compared to schizophrenia, in order to optimize 
resources and costs. A desirable perspective is the adoption of the clinical pathway 
at the regional level and in the future also at the national level.
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objeCtives: To evaluate safety and efficacy of Timolol and Brimolol 
(Brimonidine+Timolol) and study effect of aerobic exercise on intra ocular ten-
sion (IOT) in timolol treated patients. Methods: A prospective study including 90 
cases of newly diagnosed primary open angle glaucoma (POAG) from ophthalmology 
inpatients divided into 3 groups: 1-Timolol, 2-Timolol (Exercise) and 3-Brimolol.Each 
patient was administered with topical drugs followed up every 15th day. Efficacy of 
drugs were tested based on IOT measurement by Non-contact tonometer at an inter-
val of 15 days and safety on the basis of ADR check list, fundoscopy and slit lamp 
examination with tear film break up time and tear gland secretion (schirmer test).
In group 2, patients were advised to do 30 min exercise daily for 1 month. Results: 
Mean reduction in IOT was statistically significant with values as 2.7, 5& 7.9 mmHg 
and 6, 9&11 mmHg in group 1, 2 and 3 at 15th and 30th day. Frequency of ADR in 
group 1, 2&3 was 36%, 30% &40% respectively with the most frequent ADR in group 
1&2 as burning of eyes (50%) & in group 3 as dryness (22%).Effect of brimolol on 
schirmer test was significant with a mean difference of 4.33 mmHg. Frequency of 
patients missing ophthalmic doses were 60%, 48% &48% and drop out treatment 
rate was 9%,9%& 14% in group 1, 2& 3 respectively with monetary reason (most com-
mon).Most frequent cause of missing ophthalmic doses was ADR (30%) in group 1&2 
and monetary reason (43%) in group 3(predominantly in lower class).GQR-15 score 
was 35, 29&30.5 in group 1, 2 &3. ConClusions: Brimolol provides superior IOT 
lowering to timolol but is less well tolerated.Exercise along with timolol provides 
superior IOT lowering effect to timolol alone & is better tolerated, has superior visual 
QOL with reduced frequency of missed ophthalmic doses.Brimolol substantially 
reduces tear gland secretion.
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objeCtives: Psoriasis is a chronic inflammatory dermatosis that has been associ-
ated with various cardiovascular and metabolic comorbidities, including myocardial 
infarction, stroke, and diabetes mellitus. Recently, there are studies reporting the 
association of psoriasis with renal diseases. This study aimed to evaluate the risk 
of incident chronic kidney disease (CKD) and end-stage renal disease (ESRD) in 
